11.04.2024

NeoPhore presented preclinical data from our PMS2 program at the AACR Annual Meeting, San Diego, 5 - 10 April 2024.

The NeoPhore team attended the American Association for Cancer Research Annual Meeting in San Diego, 5 - 10 April 2024.

In collaboration with The University of Turin, NeoPhore presented preclinical data from our PMS2 program.

The poster presentation 'Pharmacological inhibition of PMS2 increases tumor mutational burden, induces microsatellite instability and elicits immune mediated rejection in vivo' took place on Tuesday 9th April during Session PO.ET06.05 - Novel Therapeutics and Preclinical Models .

To download the poster (only available from 15th April 2024) please submit the form below or request a copy via this email address.

NeoPhore AACR Annual Meeting 2024 Poster

More news

22.05.2024

NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb

NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb Additional funding will be used to explore…

01.02.2024

NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline

NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline • Italian investors, NE…

11.10.2023

NeoPhore presented a first disclosure of NP1867 at AACR-NCI-EORTC Conference in Boston, USA

On Saturday October 14th, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston, USA NeoPhore presented a first…

Contact us at info@neophore.com  |  
Call us +44 (0) 330 128 9990